and the inhibition of this pathway by a FGFR1 inhibitor reversed KLX's effects. These findings highlight the role of KLX in modulating key signaling pathways involved in EndMT and atherosclerosis ...

Tyra Biosciences' TYRA-300, an oral FGFR3 inhibitor, showed promising efficacy but raised concerns with some FGFR1/2-driven adverse events, causing a significant stock drop. TYRA-300 demonstrated ...

Researchers have identified in a new study that oral infigratinib, an FGFR1-3 selective tyrosine kinase inhibitor, improves ...

LUAD is frequently associated with mutations in EGFR, KRAS, ALK, and BRAF, while LUSC is more commonly linked to alterations in PIK3CA, FGFR1 ... EGFR tyrosine kinase inhibitors (TKIs) have ...

Tasurgratinib (also known as E-7090) is an oral selective FGFR1, FGFR2, and FGFR3 inhibitor that, if approved, will join other drugs in the class on the market, including Incyte’s Pemazyre ...

The most widely studied targeted therapies for the third- and further-line treatment of NSCLC are EGFR inhibitors: gefitinib, erlotinib, cetuximab and afatinib (Table 3). The most important ...